JNJ Overview

Key Data

  • Open $161.00
  • Day Range 160.85 - 167.45
  • 52 Week Range 133.65 - 173.65
  • Market Cap $422.26B
  • Shares Outstanding 2.63B
  • Public Float 2.63B
  • Beta 0.64
  • Rev. per Employee $613.92K
  • P/E Ratio 30.21
  • EPS $5.51
  • Yield 2.43%
  • Dividend $1.01
  • Ex-Dividend Date Feb 22, 2021
  • Short Interest 16.3M 03/31/21
  • % of Float Shorted 0.62%
  • Average Volume 8.08M

Performance

5 Day
  • 4.75%
1 Month
  • 4.18%
3 Month
  • 2.63%
YTD
  • 6.15%
1 Year
  • 11.61%

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 18 Full Ratings

Recent News

  • MarketWatch
  • Dow Jones

J&J to resume vaccine shipments to EU, Norway and Iceland

J&J to 'update' vaccine summary to include info on 'very rare' adverse event

Johnson & Johnson to resume COVID-19 vaccine roll out in Europe following EMA review

Why Is the Stock Market Down Today? Here Are 4 Reasons

European Health Regulators Add Blood Clot Warning to J&J’S Covid-19 Vaccine

Johnson & Johnson vaccine should get blood-clot warning, European agency says

Johnson & Johnson Just Reported Earnings. This Number Is Critical.

J&J beats profit and sales expectations, boosts dividend; COVID-19 vaccine adds $100 million to sales

J&J raises quarterly dividend by 5% to $1.06 a share

J&J revises 2021 adj. EPS outlook to $9.42-$9.57 from $9.40-$9.60

J&J Q1 pharmaceutical sales $12.20 bln vs. $11.13 bln; FactSet consensus $12.11 bln

Johnson & Johnson Q1 sales $22.32 bln vs. $20.69 bln a year ago; FactSet consensus $21.98 bln

Johnson & Johnson Q1 adj. EPS $2.59 vs. $2.30 a year ago; FactSet consensus $2.34

Johnson & Johnson Q1 EPS $2.32 vs. $2.17 a year ago

Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains

Stocks Slump as Virus Cases Rise

U.S. COVID-19 vaccine program meets key goal, but India cases and Brazil deaths worry experts

What does a strong reaction to a COVID-19 vaccine mean?

Why comparing blood clot risks from COVID-19 vaccines and birth control pills doesn’t work

Johnson & Johnson vaccine pause: What to know if you got or scheduled the shot

  • Other News
  • Press Releases

Johnson & Johnson (JNJ) Q1 2021 Earnings Call Transcript

on Motley Fool

Better-than-Expected Corporate Earnings

on Zacks.com

P&G, J&J Beat on Earnings, Drop in Pre-Market

on Zacks.com

Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe

on Zacks.com

J&J (JNJ) Q1 Earnings Top, COVID-19 Vaccine Brings $100M Sales

on Zacks.com

How Johnson & Johnson Beat Expectations in Q1

on Motley Fool

These 3 Dividend ETFs Are a Retiree's Best Friend

on Motley Fool

The Zacks Analyst Blog Highlights: Johnson & Johnson, Verizon, Dow, American Express and Honeywell

on Zacks.com

Warren Buffett Owns These 5 Dividend Aristocrats. Should You?

on Motley Fool

Johnson & Johnson (JNJ) Beats Q1 Earnings and Revenue Estimates

on Zacks.com

Pfizer (PFE)/ BioNTech to Supply Extra Comirnaty Doses to EU

on Zacks.com

3 Dividend Aristocrats to Buy and Hold Forever

on Motley Fool

Johnson & Johnson Earnings Preview: Here’s What You Need To Know

on TipRanks.com

What Did the Stock Market Do today? 3 Big Stories to Catch Up On.

on InvestorPlace.com

Why Emergent BioSolutions Stock Is Tumbling Today

on Motley Fool

2 Things Investors Need to Look For in Johnson & Johnson's Earnings Tomorrow

on Motley Fool

Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now

on Zacks.com

What Does J&J's Pause Mean for Investors?

on Motley Fool

Should You Buy Johnson & Johnson (JNJ) Ahead of Earnings?

on Zacks.com

5 Blue-Chip Stocks Likely to Gain on Q1 Earnings This Week

on Zacks.com

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Competitors

Name Chg % Market Cap
Eli Lilly & Co. 1.01% $178.19B
Sanofi ADR 0.16% $126.67B
Pfizer Inc. 0.49% $209.74B
Novartis AG ADR -0.49% $197.11B
Abbott Laboratories -4.36% $219.56B
Medtronic PLC 0.88% $169.65B
Roche Holding AG Part. Cert. 0.96% $289.23B
Stryker Corp. 0.37% $96.66B
GlaxoSmithKline PLC ADR -0.90% $92.89B
Merck & Co. Inc. 1.51% $193.97B
Competitor Data Provided ByCapital Cube Logo